Actively Recruiting
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Led by Janssen Research & Development, LLC · Updated on 2026-05-08
210
Participants Needed
38
Research Sites
300 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to better characterize the signs or symptoms of ramantamig-related taste changes.
CONDITIONS
Official Title
A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with multiple myeloma according to IMWG diagnostic criteria
- Previously treated with a proteasome inhibitor, an immunomodulatory drug, and anti CD38 monoclonal antibody
- Documented progressive disease after the last treatment regimen based on IMWG criteria
- Eastern Cooperative Oncology Group-performance status of 0 or 1 at screening, or 2 or 3 if due to stable physical limitations unrelated to multiple myeloma
- Willing and able to follow study lifestyle restrictions
You will not qualify if you...
- Known allergies, hypersensitivity, or intolerance to study drugs or their ingredients
- Stroke, transient ischemic attack, or seizure within 6 months before screening
- Severe or unstable angina, myocardial infarction, major thromboembolic event, serious heart rhythm problems, or advanced heart failure within 6 months before first dose
- Major surgery or significant injury within 2 weeks before starting treatment, or planned surgery during treatment or within 2 weeks after last dose
- Severe dysgeusia at screening or unresolved serious oral conditions such as leukoplakia, prior mouth cancers, extensive dental caries, severe periodontitis, active oral infections, candidiasis, parotid gland removal, or radiotherapy causing dry mouth
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 38 locations
1
University of California San Francisco
San Francisco, California, United States, 94143
Actively Recruiting
2
Colorado Blood Cancer Institute
Denver, Colorado, United States, 80218
Actively Recruiting
3
Yale University School Of Medicine
New Haven, Connecticut, United States, 06510
Actively Recruiting
4
Icahn School of Medicine at Mt. Sinai
New York, New York, United States, 10029
Actively Recruiting
5
University of Rochester Medical Center
Rochester, New York, United States, 14642
Actively Recruiting
6
Duke University Medical Center
Durham, North Carolina, United States, 27705
Actively Recruiting
7
University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States, 44106
Actively Recruiting
8
Virginia Commonwealth University - Massey Cancer Center
Richmond, Virginia, United States, 23298
Actively Recruiting
9
University of Washington
Seattle, Washington, United States, 98109
Actively Recruiting
10
Hospitais Integrados da Gavea SA DF Star
Brasília, Brazil, 70390-140
Actively Recruiting
11
Fundacao Universidade de Caxias do Sul
Caxias do Sul, Brazil, 95070 560
Actively Recruiting
12
Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
Curitiba, Brazil, 81520-060
Actively Recruiting
13
Instituto D Or de Pesquisa e Ensino
Salvador, Brazil, 41253 190
Actively Recruiting
14
Clinica Medica Sao Germano S/S LTDA
São Paulo, Brazil, 01455 010
Actively Recruiting
15
Instituto D Or de Pesquisa e Ensino IDOR
São Paulo, Brazil, 04543-000
Actively Recruiting
16
VUMC Amsterdam
Amsterdam, Netherlands, 1081 HV
Actively Recruiting
17
Albert Schweitzer Ziekenhuis
Dordrecht, Netherlands, 3318 AT
Actively Recruiting
18
Erasmus MC
Rotterdam, Netherlands, 3015 CN
Actively Recruiting
19
Hospital Espanol Auxilio Mutuo Auxilio Mutuo Cancer Center
San Juan, Puerto Rico, 00918
Actively Recruiting
20
Seoul National University Hospital
Seoul, South Korea, 03080
Actively Recruiting
21
The Catholic University of Korea Seoul St Mary s Hospital
Seoul, South Korea, 06591
Actively Recruiting
22
Samsung Medical Center
Seoul, South Korea, 135-230
Actively Recruiting
23
Hosp. Univ. Germans Trias I Pujol
Badalona, Spain, 08916
Actively Recruiting
24
Hosp Clinic de Barcelona
Barcelona, Spain, 08036
Actively Recruiting
25
Hosp. Univ. Virgen de La Arrixaca
El Palmar, Spain, 30120
Actively Recruiting
26
Hosp. de Jerez de La Frontera
Jerez de la Frontera, Spain, 11407
Actively Recruiting
27
Hosp. Univ. Ramon Y Cajal
Madrid, Spain, 28034
Actively Recruiting
28
Hosp. Univ. 12 de Octubre
Madrid, Spain, 28041
Actively Recruiting
29
Hosp. Quiron Madrid Pozuelo
Pozuelo de Alarcón, Spain, 28223
Actively Recruiting
30
Hosp Clinico Univ de Salamanca
Salamanca, Spain, 37007
Actively Recruiting
31
Belfast City Hospital
Belfast, United Kingdom, BT9 7AB
Actively Recruiting
32
Colchester Hospital University NHS
Colchester, United Kingdom, CO4 5JL
Actively Recruiting
33
Eastbourne District General Hospital
Eastbourne, United Kingdom, BN21 2UD
Actively Recruiting
34
The Clatterbridge Cancer Centre
Liverpool, United Kingdom, L7 8YA
Actively Recruiting
35
University College London Hospitals
London, United Kingdom, NW1 2BU
Actively Recruiting
36
Hammersmith Hospital
London, United Kingdom, W12 0HS
Actively Recruiting
37
The Christie NHS Foundation Trust Christie Hospital
Manchester, United Kingdom, M20 4BX
Actively Recruiting
38
Newcastle Freeman Hospital
Newcastle upon Tyne, United Kingdom, NE7 7DN
Actively Recruiting
Research Team
S
Study Contact
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
6
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here